Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $95.25 Average Price Target from Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been assigned an average rating of "Buy" from the eleven brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $95.25.

Several analysts have weighed in on JANX shares. Wedbush reaffirmed an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. Scotiabank cut their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. Finally, HC Wainwright reissued a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a research note on Monday, March 3rd.

Janux Therapeutics Trading Up 0.0%

Shares of Janux Therapeutics stock traded up $0.01 on Tuesday, reaching $25.22. The stock had a trading volume of 1,181,341 shares, compared to its average volume of 874,124. The business's 50 day moving average is $28.03 and its two-hundred day moving average is $39.49. The company has a market cap of $1.49 billion, a P/E ratio of -21.56 and a beta of 3.24. Janux Therapeutics has a 1 year low of $22.48 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities analysts anticipate that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $30.00, for a total transaction of $100,020.00. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at $2,464,170. This represents a 3.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were bought at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the acquisition, the director now directly owns 10,141,287 shares in the company, valued at $314,582,722.74. This trade represents a 1.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 10,001 shares of company stock worth $313,964 in the last 90 days. 29.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. increased its stake in shares of Janux Therapeutics by 7.9% in the first quarter. RA Capital Management L.P. now owns 11,189,693 shares of the company's stock worth $302,122,000 after buying an additional 824,041 shares during the period. FMR LLC boosted its holdings in shares of Janux Therapeutics by 10.8% during the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock worth $464,189,000 after purchasing an additional 845,266 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Janux Therapeutics by 19.4% during the first quarter. Adage Capital Partners GP L.L.C. now owns 3,654,574 shares of the company's stock worth $98,673,000 after purchasing an additional 592,824 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Janux Therapeutics by 41.2% during the fourth quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company's stock worth $190,617,000 after purchasing an additional 1,038,996 shares during the period. Finally, Paradigm Biocapital Advisors LP boosted its holdings in shares of Janux Therapeutics by 46.5% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock worth $188,246,000 after purchasing an additional 1,115,412 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.